Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Morgan Stanley initiated coverage of GSK (GSK) with an Equal Weight rating and 1,450 GBp price target The shares trade at an inexpensive ...

After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...

A TASKFORCE will aim to allocate £2 million to a successful project in Ulverston by June as a ‘lasting legacy’ from a pharmaceutical ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...

Today, the Natural History Museum, London, announced the first new permanent gallery to open since 2016, Fixing Our Broken Planet, which will open 3 April 2025. The gallery and a new programme of ...

Odyssey layoffs, GSK relocates vaccine R&D, Aligos raises $105M, Terrain Bio launches, Gates Foundation backs antibiotics research, Neuphoria gets Merck milestone ...